Beactica Announces Drug Discovery Collaboration With Arrow Therapeutics
"We are very pleased to be working with Arrow" said Beactica's CEO, Dr Per Kallblad. "The company has a world-class reputation for conducting break through research in the antiviral field and we look forward to applying our technology on their targets."
CEO of Arrow Therapeutics, Dr Ken Powell, said "Working with Beactica provides us with an opportunity to apply a new technology that has already shown strong potential."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.